Education
About Us
Working with TipRanks
Follow Us
Dyadic International Inc. (DYAI)
:DYAI
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.07Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -12.50%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Dyadic's transition towards commercializing non-pharmaceutical products and securing strategic partnerships with milestone payments. However, the call also reflected concerns over reduced collaborations and a decrease in cash reserves, alongside a consistent net loss. The focus on non-pharmaceutical commercialization and milestone achievements suggests a promising outlook despite the financial challenges.Company Guidance
During the Dyadic International First Quarter 2025 Financial Results Conference Call, the guidance provided highlighted strategic shifts and upcoming initiatives aimed at driving revenue growth. The company emphasized its focus on commercializing non-pharmaceutical products across life sciences, bioactives, ingredients, and industrial sectors, leveraging its proprietary C1 and Dapibus microbial expression platforms. Dyadic anticipates launching recombinant human serum albumin in Q3 2025, targeting a $6.1 billion cell culture media market, and expects a third milestone payment in Q2 related to productivity improvements. The company is also advancing recombinant transferrin and fibroblast growth factors, with plans for Q2 sampling. In DNA/RNA tools, Dyadic is progressing with DNase1 and other enzyme prototypes targeting a $4 billion market by 2028. Furthermore, developments in animal-free dairy proteins, with a market value of $26.5 billion in 2023, include alpha-lactalbumin and human lactoferrin, with sampling efforts anticipated in late 2025. In industrial applications, Dyadic's EN3ZYME, launched in 2024, received a large follow-on order in Q1 2025. Financially, Dyadic reported Q1 2025 revenue of approximately $394,000, a net loss of $2,028,000, and cash reserves of $7.4 million as of March 31, 2025, as the company aims to support near-term revenue growth and strategic objectives.Increase in Total Revenue
Total revenue for the quarter ended March 31, 2025 increased to approximately $394,000 compared to $335,000 for the same period 1 year ago.
Major Collaboration and Grant Achievements
Dyadic secured a $4.5 million grant from CEPI and a $3 million program funded by the Gates Foundation, contributing to non-dilutive funding for vaccine and antibody development.
Commercialization of Non-Pharmaceutical Products
Focus on commercial-ready non-pharmaceutical products, including the expected launch of recombinant human serum albumin in Q3 2025 and ongoing development of other enzyme products.
Strategic Partnerships and Milestone Payments
Anticipation of achieving a third milestone payment related to productivity improvements in Q2 2025.
Cost Reduction
G&A expenses decreased by 10.8% to $1,596,000 compared to $1,789,000 for the same period a year ago.
Progress in Industrial Applications
Significant progress with enzyme systems that enhance process efficiency, including a large follow-on purchase order for EN3ZYME from Fermbox Bio.
DYAI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DYAI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.04 | $1.00 | -3.85% |
Mar 26, 2025 | $1.33 | $1.35 | +1.50% |
Nov 12, 2024 | $1.14 | $1.12 | -1.75% |
Aug 13, 2024 | $1.35 | $1.36 | +0.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dyadic International Inc. (DYAI) report earnings?
Dyadic International Inc. (DYAI) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Dyadic International Inc. (DYAI) earnings time?
Dyadic International Inc. (DYAI) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DYAI EPS forecast?
DYAI EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.